Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed Form 6-K on March 16, 2026. The report discloses a corporate development regarding a collaboration between NeuroThera Labs and Clearmind Medicine, which resulted in a patent application for a depression therapy.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves to announce a strategic milestone rather than report periodic financial results.
Guidance, Outlook, and Risks
Management Commentary: The company highlighted the successful collaboration leading to a patent application for depression therapy.
Risks and Contingencies: The filing text does not provide specific details regarding risks, contingencies, or unusual items beyond the standard incorporation of the press release.
Key Facts for Investor Verification
- Verify the status and scope of the patent application for depression therapy resulting from the NeuroThera Labs-Clearmind Medicine collaboration.
- Confirm the commercialization timeline and potential revenue impact of the new therapy.
- Review the full text of the press release (Exhibit 99.1) for details on the partnership agreement.